- Home
- BPRN vs MGNX Comparison
BPRN vs MGNX Comparison
Compare BPRN & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPRN
- MGNX
- Stock Information
- Founded
- BPRN 2007
- MGNX 2000
- Country
- BPRN United States
- MGNX United States
- Employees
- BPRN 246
- MGNX N/A
- Industry
- BPRN Major Banks
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- BPRN Finance
- MGNX Health Care
- Exchange
- BPRN Nasdaq
- MGNX Nasdaq
- Market Cap
- BPRN 216.1M
- MGNX 202.7M
- IPO Year
- BPRN N/A
- MGNX 2013
- Fundamental
- Price
- BPRN $31.40
- MGNX $2.76
- Analyst Decision
- BPRN Strong Buy
- MGNX Hold
- Analyst Count
- BPRN 1
- MGNX 10
- Target Price
- BPRN $35.00
- MGNX $7.17
- AVG Volume (30 Days)
- BPRN 9.2K
- MGNX 768.5K
- Earning Date
- BPRN 01-28-2025
- MGNX 03-06-2025
- Dividend Yield
- BPRN 3.82%
- MGNX N/A
- EPS Growth
- BPRN N/A
- MGNX N/A
- EPS
- BPRN 1.55
- MGNX N/A
- Revenue
- BPRN $69,578,000.00
- MGNX $141,329,000.00
- Revenue This Year
- BPRN N/A
- MGNX $174.73
- Revenue Next Year
- BPRN $16.24
- MGNX N/A
- P/E Ratio
- BPRN $20.26
- MGNX N/A
- Revenue Growth
- BPRN 0.35
- MGNX 16.68
- 52 Week Low
- BPRN $29.02
- MGNX $2.34
- 52 Week High
- BPRN $39.35
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- BPRN 42.40
- MGNX 45.32
- Support Level
- BPRN $31.13
- MGNX $2.34
- Resistance Level
- BPRN $32.69
- MGNX $2.95
- Average True Range (ATR)
- BPRN 0.81
- MGNX 0.17
- MACD
- BPRN 0.02
- MGNX 0.03
- Stochastic Oscillator
- BPRN 25.30
- MGNX 61.76
About BPRN Princeton Bancorp Inc. (PA)
Princeton Bancorp Inc is a banking company. It is a full-service financial institution that provides business and personal banking. Its personal banking and business banking services include checking accounts and savings accounts. It offers traditional retail banking services, one-to-four-family residential mortgage loans, multi-family and commercial mortgage loans, construction loans, commercial business loans, and consumer loans, including home equity loans and lines of credit. The Bank also has two retail branches and conducts loan origination activities in select areas of the New York City metropolitan area.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).